Advancing Dry Powder Inhaler Systems Through Digital Health Integration: A Systematic Review Of Current Developments, Regulatory Frameworks, And Emerging Future Directions

Dry powder inhalers (DPIs) have become one of the most widely adopted pulmonary drug delivery systems because of their portability, propellant-free operation, formulation stability, and ability to deliver medications directly to the respiratory tract. Despite significant technological progress, conventional DPIs remain limited by their inability to objectively monitor patient adherence, inhalation technique, inspiratory flow variability, and real-time treatment outcomes. These limitations contribute to suboptimal disease control in chronic respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The rapid emergence of digital health technologies, including artificial intelligence (AI), Internet of Medical Things (IoMT), cloud computing, digital sensors, and mobile health platforms, has introduced new opportunities to transform conventional inhalation devices into intelligent therapeutic systems capable of continuous monitoring, personalized intervention, and data-driven clinical decision-making. This systematic review critically examines the current state of digital dry powder inhaler technologies by integrating evidence from recent developments in inhaler engineering, digital monitoring platforms, inhalation analytics, regulatory science, and patient-centered healthcare models.

The review synthesizes evidence from the selected literature to evaluate technological innovations in digital DPIs, including sensor-enabled adherence monitoring, inspiratory flow analysis, AI-assisted inhalation assessment, cloud-based healthcare integration, and remote disease management platforms. Particular attention is given to the evolving regulatory landscape governing digital inhalers, including device validation, software integration, cybersecurity, interoperability, clinical performance evaluation, and post-market surveillance. The review also explores challenges associated with technical standardization, patient usability, data privacy, economic feasibility, and clinical implementation. Comparative analysis demonstrates that digital integration significantly enhances treatment adherence, enables early identification of inhalation errors, supports personalized respiratory care, and improves healthcare efficiency while introducing new regulatory and implementation complexities. Recent investigations into digital inhaler platforms further demonstrate the growing importance of connected respiratory devices for long-term disease monitoring and adherence optimization (Aung et al., 2025).

The findings indicate that future DPI systems will increasingly evolve toward intelligent, connected, and predictive healthcare ecosystems supported by artificial intelligence, machine learning, remote patient monitoring, and real-time clinical analytics. Successful implementation, however, requires multidisciplinary collaboration among pharmaceutical scientists, device engineers, software developers, clinicians, regulatory authorities, and healthcare organizations. The review contributes a comprehensive synthesis of current developments while identifying future research priorities necessary for achieving safe, effective, and globally standardized digital inhaler technologies.

Dry powder inhalers, Digital health, Artificial intelligence, Smart inhalers, Respiratory drug delivery

Aung HWW, Murphy A, Greening NJ, The evolving landscape of digital inhaler platforms and adherence support in chronic airways disease. Chronic Respir Dis, 2025;22:1-15.

Capstick TGD, Gudimetla S, Harris DS, Malone R, Usmani OS, Demystifying dry powder inhaler resistance with relevance to optimal patient care. Clin Drug Investig, 2024;44:109-114.

de Boer AH, Hagedoorn P, Hoppentocht M, Buttini F, Grasmeijer F, Frijlink HW, Dry powder inhalation: past, present and future. Expert Opin Drug Deliv. 2017;14(4):499-512.

Fan Z, Ye Y, Chen J, Ma Y, Zhu J, Development of an AI-empowered novel digital monitoring system for inhalation flow profiles. Sensors, 2025;25:4402.

Kainu A, Successful use of Easyhaler dry powder inhaler in patients with chronic obstructive pulmonary disease: analysis of peak inspiratory flow from three clinical trials. Pulm Ther. 2024;10:133-142.

Kocks JWH, Identifying critical inhalation technique errors in dry powder inhaler use in patients with COPD based on the association with health status and exacerbations: findings from the multicountry cross-sectional observational PIFotal study. BMC Pulm Med, 2023;23:302.

Palem CR, Comprehensive Review on Dry Powder Inhalations: Mechanisms, Technologies, and Future Directions. American Journal of PharmTech Research, 2025.

Palem CR, Lekkala VK, Nagamalli NK, Balguri PR, Gumudevelli S, Next-generation dry powder inhalers: advances in characterization and evolving regulatory frameworks. J Pharm Sci, 2025;1(9):160-177.

Palem CR, Nagamalli NK, Paidi VS, Lekkala VK, Rendla R, Gumudevelli S, Dry powder inhalation device development and patent challenges: a comprehensive review. J Pharm Sci, 2025;1(12):436-453.

Palem CR, Noolu P, Chilukoti V, Balguri PR, Nagamalli NK, Gumudevelli S. Design and evaluation of controlled-release floating metformin HCl tablets: Influence of binder and granulation process on buoyancy. J Pharm Res Int, 2025;37(12):234-244.

Palem CR, Rendla R, Nagamalli NK, Lekkala VK, Gumudevelli S, A comprehensive review of current trends and regulatory frameworks in generic drug development. J Pharm Sci, 2025;1(10):16-27.

Pleasants RA, Integrating digital inhalers into clinical care of patients with asthma and chronic obstructive pulmonary disease. Respir Med, 2022;205:107038.

Watson A, Wilkinson TMA, Digital healthcare in COPD management: a narrative review on the advantages, pitfalls, and need for further research. Ther Adv Respir Dis, 2022;16:1-23.

Xiroudaki S, Schoubben A, Giovagnoli S, Rekkas DM, Dry powder inhalers in the digitalization era: current status and future perspectives. Pharmaceutics, 2021;13:1455.